A number of other equities analysts also recently commented on the company. Wedbush began coverage on Liquidia Technologies in a research report on Tuesday, September 4th. They set an outperform rating and a $26.00 price objective for the company. Jefferies Financial Group began coverage on Liquidia Technologies in a research report on Monday, August 20th. They set a buy rating and a $22.00 price objective for the company. Finally, Needham & Company LLC began coverage on Liquidia Technologies in a research report on Monday, August 20th. They set a buy rating and a $30.00 price objective for the company.
NASDAQ LQDA traded up $0.78 during trading on Wednesday, hitting $17.16. The stock had a trading volume of 778 shares, compared to its average volume of 62,190. Liquidia Technologies has a twelve month low of $10.52 and a twelve month high of $38.46.
About Liquidia Technologies
Liquidia Technologies, Inc is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. PRINT technology is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies.
Read More: Insider Trading – What You Need to Know
Receive News & Ratings for Liquidia Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia Technologies and related companies with MarketBeat.com's FREE daily email newsletter.